# Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

> **NCT02357810** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 178 (actual)

## Conditions studied

- Adult Liposarcoma
- Metastatic Liposarcoma
- Metastatic Osteosarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Liposarcoma
- Recurrent Osteosarcoma
- Stage IV Adult Soft Tissue Sarcoma

## Interventions

- **DRUG:** Pazopanib Hydrochloride
- **DRUG:** Oral Topotecan Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02357810
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-21
- **Primary completion:** 2018-04-27
- **Final completion:** 2021-10-12
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2022-06-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02357810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02357810, "Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02357810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*